Developing Biomarkers in Pancreatic Cancer
- To determine whether the cellular localization of BRCA1 can predict how patients with
pancreatic cancer will respond to cytotoxic agents (e.g., fluorouracil or gemcitabine
hydrochloride) or radiotherapy.
- To identify pre-treatment markers that can be used to correlate with clinical outcomes
of survival and recurrence.
- To determine if a method of extracting and identifying secreted cytokines and growth
factors from biopsy tissue can now be applied to the pancreatic cancer population.
OUTLINE: Tissue samples from biopsies performed during pancreatectomy are collected from the
Vanderbilt Ingram Cancer Center Human Tissue Acquisition Core for laboratory biomarker
studies. Proteins secreted by cancer cells and/or cancer-associated cells are studied by
extracting and identifying secreted cytokines and growth factors from biopsy tissue. The
integrity of the DNA repair pathway in pancreatic cancer is analyzed by Rad51 and
phosphorylated DNA-PK foci formation. Markers are correlated with clinical outcome.
Patients are followed for recurrence, relapse, and death from disease.
Observational Model: Case-Only, Time Perspective: Prospective
Cellular localization of BRCA1 as a predictor of response to cytotoxic agents or radiotherapy
Examine the location of BRCA1 in the cells and determine if this location predicts patient response to the chemotherapy drugs given
following collection of all pancreatic tissue specimens and patient outcome data
A. Bapsi Chakravarthy, MD
Vanderbilt-Ingram Cancer Center
United States: Food and Drug Administration
VICC GI 0717
|Vanderbilt-Ingram Cancer Center||Nashville, Tennessee 37232-6838|
|Vanderbilt-Ingram Cancer Center - Cool Springs||Nashville, Tennessee 37064|
|Vanderbilt-Ingram Cancer Center at Franklin||Nashville, Tennessee 37064|